Clinical response to sodium glucose co-transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma.
Keita IzumiYasumasa IimuraKiyoshi HirumaTsuguhiro ToumaTetsuro TsukamotoPublished in: IJU case reports (2019)
Sodium glucose co-transporter 2 inhibitors are potentially applicable as anticancer agents among patients with metastatic renal cell carcinoma.